Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Spero Therapeutics, Inc.SPRO · Entity 7014 | Chief Operating Officer | February 06, 2026 | February 10, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Spero Therapeutics, Inc.
Report date February 06, 2026 · Filed February 10, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 742,506 |
Reported balance
After 2026-02-06 transaction · row 1
1 source rowRow 1 · 2026-02-06 · Sale · Disposed 18,652 · Balance 742,506 F1: Represents shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of RSUs. The sale occurred automatically to satisfy the tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary trade by the Reporting Person. |
Filing footnotes · ownership attribution and instrument terms
F1: Represents shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of RSUs. The sale occurred automatically to satisfy the tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary trade by the Reporting Person.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| February 06, 2026 Filed Feb 10, 2026 02:09 UTC | Spero Therapeutics, Inc. SPRO · Entity 7014 | SaleCommon Stock | 18,652 | $2.36 | $44,018.72 |
DisclosureSEC source: 0001193125-26-043315 · ownership.xml · nonDerivative · entry 1 Keutzer Timothy · CIK 0001798155 · Chief Operating Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 742,506 F1 · kind: Represents shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of RSUs. The sale occurred automatically to satisfy the tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary trade by the Reporting Person. F1 · shares: Represents shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of RSUs. The sale occurred automatically to satisfy the tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary trade by the Reporting Person. Read SEC document |
| February 04, 2026 Filed Feb 5, 2026 11:30 UTC | Spero Therapeutics, Inc. SPRO · Entity 7014 | SaleCommon Stock | 3,471 | $2.24 | $7,775.04 |
DisclosureSEC source: 0001193125-26-038441 · ownership.xml · nonDerivative · entry 4 Keutzer Timothy · CIK 0001798155 · Chief Operating Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 761,158 F2 · kind: Represents shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of RSUs. The sale occurred automatically to satisfy the tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary trade by the Reporting Person. F2 · shares: Represents shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of RSUs. The sale occurred automatically to satisfy the tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary trade by the Reporting Person. Read SEC document |
| February 03, 2026 Filed Feb 5, 2026 11:30 UTC | Spero Therapeutics, Inc. SPRO · Entity 7014 | SaleCommon Stock | 24,224 | $2.14 | $51,839.36 |
DisclosureSEC source: 0001193125-26-038441 · ownership.xml · nonDerivative · entry 3 Keutzer Timothy · CIK 0001798155 · Chief Operating Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 764,629 F2 · kind: Represents shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of RSUs. The sale occurred automatically to satisfy the tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary trade by the Reporting Person. F2 · shares: Represents shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of RSUs. The sale occurred automatically to satisfy the tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary trade by the Reporting Person. Read SEC document |
| February 02, 2026 Filed Feb 5, 2026 11:30 UTC | Spero Therapeutics, Inc. SPRO · Entity 7014 | GrantStock Option (Right to Buy) · Derivative | 137,000 | $0.00 Strike: $2.23 | $0.00 |
DisclosureSEC source: 0001193125-26-038441 · ownership.xml · derivative · entry 5 Keutzer Timothy · CIK 0001798155 · Chief Operating Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 137,000 Underlying: Common Stock · 137,000 shares Expires 2026-02-02 F3 · derivative.exercise_date: The shares underlying this option vest as to 25% on February 2, 2027, with the remainder vesting in 36 equal monthly installments thereafter, subject to the Reporting Person's continued service through the applicable vesting date. Read SEC document |
| February 02, 2026 Filed Feb 5, 2026 11:30 UTC | Spero Therapeutics, Inc. SPRO · Entity 7014 | SaleCommon Stock | 18,891 | $2.20 | $41,560.20 |
DisclosureSEC source: 0001193125-26-038441 · ownership.xml · nonDerivative · entry 2 Keutzer Timothy · CIK 0001798155 · Chief Operating Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 788,853 F2 · kind: Represents shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of RSUs. The sale occurred automatically to satisfy the tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary trade by the Reporting Person. F2 · shares: Represents shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of RSUs. The sale occurred automatically to satisfy the tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary trade by the Reporting Person. Read SEC document |
| February 02, 2026 Filed Feb 5, 2026 11:30 UTC | Spero Therapeutics, Inc. SPRO · Entity 7014 | GrantCommon Stock | 68,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001193125-26-038441 · ownership.xml · nonDerivative · entry 1 Keutzer Timothy · CIK 0001798155 · Chief Operating Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 807,744 F1 · shares: Consists of restricted stock units ("RSUs") granted to Reporting Person under Issuer's 2017 Stock Incentive Plan. Each RSU represents the right to receive one share of common stock upon vesting. The RSUs vest in four equal annual installments beginning on February 2, 2027, subject to the Reporting Person's continued service through the applicable vesting date. Read SEC document |
| August 28, 2025 Filed Sep 3, 2025 10:02 UTC | Spero Therapeutics, Inc. SPRO · Entity 7014 | SaleCommon Stock | 1,695 | $1.97 | $3,339.15 |
DisclosureSEC source: 0000950170-25-112659 · ownership.xml · nonDerivative · entry 1 Keutzer Timothy · CIK 0001798155 · Chief Operating Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 739,744 F1 · kind: The reported transaction is a sale of common stock effected to cover tax withholding obligations pursuant to a "sell to cover" provision included in each RSU Agreement in connection with the vesting of restricted stock units ("RSUs") that were granted to the Reporting Person on August 26, 2021. F1 · shares: The reported transaction is a sale of common stock effected to cover tax withholding obligations pursuant to a "sell to cover" provision included in each RSU Agreement in connection with the vesting of restricted stock units ("RSUs") that were granted to the Reporting Person on August 26, 2021. Read SEC document |
| February 05, 2025 Filed Feb 6, 2025 02:04 UTC | Spero Therapeutics, Inc. SPRO · Entity 7014 | SaleCommon Stock | 24,920 | $0.78 | $19,437.60 |
DisclosureSEC source: 0000950170-25-014866 · ownership.xml · nonDerivative · entry 4 Keutzer Timothy · CIK 0001798155 · Chief Operating Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 741,439 F4 · kind: The reported transaction is a sale of common stock effected to cover tax withholding obligations pursuant to a "sell to cover" provision included in each RSU Agreement in connection with the vesting of RSUs that were granted to the Reporting Person on February 1, 2024. Read SEC document |
| February 05, 2025 Filed Feb 6, 2025 02:04 UTC | Spero Therapeutics, Inc. SPRO · Entity 7014 | SaleCommon Stock | 27,643 | $0.78 | $21,561.54 |
DisclosureSEC source: 0000950170-25-014866 · ownership.xml · nonDerivative · entry 3 Keutzer Timothy · CIK 0001798155 · Chief Operating Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 766,359 F3 · kind: The reported transaction is a sale of common stock effected to cover tax withholding obligations pursuant to a "sell to cover" provision included in each RSU Agreement in connection with the vesting of RSUs that were granted to the Reporting Person on February 1, 2023. Read SEC document |
| February 05, 2025 Filed Feb 6, 2025 02:04 UTC | Spero Therapeutics, Inc. SPRO · Entity 7014 | SaleCommon Stock | 3,974 | $0.78 | $3,099.72 |
DisclosureSEC source: 0000950170-25-014866 · ownership.xml · nonDerivative · entry 2 Keutzer Timothy · CIK 0001798155 · Chief Operating Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 794,002 F2 · kind: The reported transaction is a sale of common stock effected to cover tax withholding obligations pursuant to a "sell to cover" provision included in each RSU Agreement in connection with the vesting of RSUs that were granted to the Reporting Person on February 1, 2022. Read SEC document |
| February 03, 2025 Filed Feb 6, 2025 02:04 UTC | Spero Therapeutics, Inc. SPRO · Entity 7014 | GrantCommon Stock | 266,139 | $0.00 | $0.00 |
DisclosureSEC source: 0000950170-25-014866 · ownership.xml · nonDerivative · entry 1 Keutzer Timothy · CIK 0001798155 · Chief Operating Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 797,976 F1 · shares: Consists of restricted stock units ("RSUs"). Each RSU represents the right to receive one share of common stock upon vesting. The RSUs vest in four equal annual installments beginning on February 3, 2026, subject to the Reporting Person's continued service through the applicable vesting date. Read SEC document |
| August 27, 2024 Filed Aug 29, 2024 22:42 UTC | Spero Therapeutics, Inc. SPRO · Entity 7014 | SaleCommon Stock | 2,213 | $1.35 | $2,987.55 |
DisclosureSEC source: 0000950170-24-101998 · ownership.xml · nonDerivative · entry 1 Keutzer Timothy · CIK 0001798155 · Chief Operating Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 531,837 F1 · kind: The reported transaction is a sale of common stock effected to cover tax withholding obligations pursuant to a "sell to cover" provision included in each RSU Agreement in connection with the vesting of RSUs that were granted to the Reporting Person on August 26, 2021. Read SEC document |
| February 02, 2024 Filed Feb 6, 2024 01:53 UTC | Spero Therapeutics, Inc. SPRO · Entity 7014 | SaleCommon Stock | 30,971 | $1.36 | $42,120.56 |
DisclosureSEC source: 0000950170-24-011501 · ownership.xml · nonDerivative · entry 2 Keutzer Timothy · CIK 0001798155 · Chief Operating Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 534,050 F2 · kind: The reported transaction is a sale of common stock effected to cover tax withholding obligations in connection with the vesting of RSUs that were granted to the Reporting Person on February 1, 2022 and February 1, 2023 pursuant to a "sell to cover" provision included in each RSU Agreement. F3 · price: Represents the weighted average sales price per share. The shares sold at prices ranging from $1.36 to $1.42 per share. Full information regarding the number of shares sold at each price shall be provided upon request to the staff of the U.S. Securities and Exchange Commission, the Issuer, or a security holder of the Issuer. Read SEC document |
| February 01, 2024 Filed Feb 6, 2024 01:53 UTC | Spero Therapeutics, Inc. SPRO · Entity 7014 | GrantCommon Stock | 239,731 | $0.00 | $0.00 |
DisclosureSEC source: 0000950170-24-011501 · ownership.xml · nonDerivative · entry 1 Keutzer Timothy · CIK 0001798155 · Chief Operating Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 565,021 F1 · shares: Consists of restricted stock units ("RSUs"). Each RSU represents the right to receive one share of common stock upon vesting. The RSUs vest in four equal annual installments beginning on February 1, 2025, subject to the Reporting Person's continued service through the applicable vesting date. Read SEC document |
| August 28, 2023 Filed Aug 30, 2023 20:23 UTC | Spero Therapeutics, Inc. SPRO · Entity 7014 | SaleCommon Stock | 1,854 | $1.26 | $2,336.04 |
DisclosureSEC source: 0000950170-23-045450 · ownership.xml · nonDerivative · entry 1 Keutzer Timothy · CIK 0001798155 · Chief Development Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 325,290 F1 · kind: The reported transaction is a sale of common stock effected to cover tax withholding obligations in connection with the vesting of restricted stock units ("RSUs") that were granted to the Reporting Person on August 26, 2021 pursuant to a "sell to cover" provision included in the RSU Agreement. Read SEC document |
| February 02, 2023 Filed Feb 4, 2023 00:43 UTC | Spero Therapeutics, Inc. SPRO · Entity 7014 | SaleCommon Stock | 3,394 | $1.86 | $6,312.84 |
DisclosureSEC source: 0000899243-23-003948 · doc4.xml · nonDerivative · entry 2 Keutzer Timothy · CIK 0001798155 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 327,144 F3 · kind: The reported transaction is a sale of common stock effected to cover tax withholding obligations in connection with the vesting of RSUs that were granted to the Reporting Person on February 1, 2022 pursuant to a "sell to cover" provision included in the RSU Agreement. F2 · balance_after: Includes 312,518 RSUs held by the Reporting Person. Read SEC document |
| February 01, 2023 Filed Feb 4, 2023 00:43 UTC | Spero Therapeutics, Inc. SPRO · Entity 7014 | GrantCommon Stock | 265,957 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-23-003948 · doc4.xml · nonDerivative · entry 1 Keutzer Timothy · CIK 0001798155 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 330,538 F1 · shares: Consists of restricted stock units ("RSUs"). Each RSU represents the right to receive one share of common stock upon vesting. The RSUs vest in four equal annual installments beginning on February 1, 2024, subject to the Reporting Person's continued service through the applicable vesting date. F2 · balance_after: Includes 312,518 RSUs held by the Reporting Person. Read SEC document |
| February 01, 2022 Filed Feb 3, 2022 21:18 UTC | Spero Therapeutics, Inc. SPRO · Entity 7014 | GrantStock Option (Right to Buy) · Derivative | 53,190 | $0.00 Strike: $11.18 | $0.00 |
DisclosureSEC source: 0000899243-22-004589 · doc4.xml · derivative · entry 2 Keutzer Timothy · CIK 0001798155 · Chief Development Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 53,190 Underlying: Common Stock · 53,190 shares Expires 2032-02-01 F3 · derivative.exercise_date: The shares underlying this option vest as to 25% on February 1, 2023, with the remainder vesting in 36 equal monthly installments thereafter, subject to the Reporting Person's continued service through the applicable vesting date. Read SEC document |
| February 01, 2022 Filed Feb 3, 2022 21:18 UTC | Spero Therapeutics, Inc. SPRO · Entity 7014 | GrantCommon Stock | 38,014 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-22-004589 · doc4.xml · nonDerivative · entry 1 Keutzer Timothy · CIK 0001798155 · Chief Development Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 64,581 F1 · shares: Consists of restricted stock units ("RSUs"). Each RSU represents the right to receive one share of common stock upon vesting. The RSUs vest in four equal annual installments beginning on February 1, 2023, subject to the Reporting Person's continued service through the applicable vesting date. F2 · balance_after: Includes 2,500 shares of common stock and 62,081 RSUs held by the Reporting Person. Read SEC document |
| August 26, 2021 Filed Aug 30, 2021 20:15 UTC | Spero Therapeutics, Inc. SPRO · Entity 7014 | GrantCommon Stock | 24,067 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-21-034499 · doc4.xml · nonDerivative · entry 1 Keutzer Timothy · CIK 0001798155 · Chief Development Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 26,567 F1 · shares: Consists of restricted stock units ("RSUs"). Each RSU represents the right to receive one share of common stock upon vesting. The RSUs vest in four equal annual installments beginning on August 26, 2022, subject to the Reporting Person's continued service through the applicable vesting date. Read SEC document |
| February 01, 2021 Filed Feb 4, 2021 00:52 UTC | Spero Therapeutics, Inc. SPRO · Entity 7014 | GrantStock Option (Right to Buy) · Derivative | 57,432 | $0.00 Strike: $19.18 | $0.00 |
DisclosureSEC source: 0000899243-21-004790 · doc4.xml · derivative · entry 1 Keutzer Timothy · CIK 0001798155 · Chief Development Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 57,432 Underlying: Common Stock · 57,432 shares Expires 2031-02-01 F1 · derivative.exercise_date: The shares underlying this option vest as to 25% on February 1, 2022, with the remainder vesting in 36 equal monthly installments thereafter, subject to the Reporting Person's continued service through the applicable vesting date. Read SEC document |
| February 03, 2020 Filed Feb 3, 2020 22:28 UTC | Spero Therapeutics, Inc. SPRO · Entity 7014 | GrantStock Option (Right to Buy) · Derivative | 55,000 | $0.00 Strike: $9.34 | $0.00 |
DisclosureSEC source: 0000899243-20-002604 · doc4.xml · derivative · entry 1 Keutzer Timothy · CIK 0001798155 · Chief Development Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 55,000 Underlying: Common Stock · 55,000 shares Expires 2030-02-03 F1 · derivative.exercise_date: The shares underlying this option vest as to 25% on February 3, 2021, with the remainder vesting in 36 equal monthly installments thereafter, subject to the Reporting Person's continued service through the applicable vesting date. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.